death effector domain containing 2Genealiases: FLAME-3 · FLAME3
Q-omics provides the consensus-scored DEDD2 profile across patient tissues and cancer cell-line models. DEDD2 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, DEDD2 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, DEDD2 RNA expression shows 19,417 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRP, KIRC, and ACC as cancer lineages where DEDD2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DEDD2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DEDD2 survival associations across molecular data types. DEDD2 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DEDD2 RNA expression–survival associations across cancer types. High DEDD2 expression shows unfavorable associations in KIRP, LUAD, LGG and UVM, but favorable associations in KIRC and BLCA. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify KIRP as the clearest survival context for DEDD2 RNA expression.
This table summarizes DEDD2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for DEDD2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DEDD2 shows lower tumor expression in THCA and higher tumor expression in KIRC, HNSC, STAD, LIHC and BRCA. The KIRC box plot shows higher DEDD2 RNA expression in tumor versus normal tissue (log2 FC = +0.489, t-test p < 0.001).
This table shows molecular features associated with DEDD2 in patient tissues and cancer cell lines. In patient samples, DEDD2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, DEDD2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Lymphoma.
